New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
11:58 EDTALNYAlnylam updates increase confidence in upcoming data, says Piper Jaffray
After Alnylam presented new data on its Phase II study of patisiran in patients with Familial Amyloidotic Polyneuropathy, PiperJaffray says that the data increases its optimism about the outlook for a Phase III trial of the treatment in 2016. The firm keeps an Overweight rating on the stock.
News For ALNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 21, 2015
06:08 EDTALNYAlnylam 4.737M share Secondary priced at $95.00
Subscribe for More Information
January 11, 2015
20:08 EDTALNYAlnylam announces updated results of ALN-AT3 Phase 1 study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use